NCT05907954 2026-03-16(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaIDEAYA BiosciencesPhase 2 Active not recruiting160 enrolled
NCT01490632 2019-09-27A Phase 2b Study of Baricitinib in Participants With Moderate to Severe PsoriasisEli Lilly and CompanyPhase 2 Completed271 enrolled 32 charts